Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Income Tax Provision 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: -135.69%

Cyteir Therapeutics Inc Income Tax Provision 1 year YoY Change (%) is -135.69% for the Trailing 12 Months (TTM) ending September 30, 2023. Income Tax Provision is the amount of income tax expenses recorded by a company in a given period. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Cyteir Therapeutics Inc Income Tax Provision for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -989.00 K.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends